血液透析动静脉瘘疗效与安全性系统评价及荟萃分析
该系统评价与荟萃分析纳入318项研究共62712个血管通路,评估动静脉瘘的通畅率、感染、成熟与废弃结局。结果显示一年一期未辅助、一期辅助和二期通畅率分别为64%、73%和79%,但仅26%的瘘在6个月时成熟,21%未使用即被废弃,总体感染风险为4.1%。作者指出报告的通畅率可能高估临床效用,需统一结局定义。
要点
- 一年一期未辅助、一期辅助和二期通畅率分别为64%、73%和79%。
- 仅26%的瘘在6个月时成熟,平均成熟时间3.5个月,21%未使用即废弃。
- 总体感染风险4.1%,每100个通路日感染率为0.018。
核心结论
- 报告的通畅率在考虑成熟时间、成熟率、废弃和感染后可能高估动静脉瘘的临床效用。
- 成熟时间延长、废弃和感染均显著影响评估动静脉瘘创建的临床效用。
- 需要严格且一致的血液透析通路结局定义以明确瘘成功因素和失败临床后果。
研究设计与样本
- 系统评价与荟萃分析,检索多个数据库识别观察性和干预性研究。
- 共纳入318项研究,涵盖62712个血管通路。
- 使用数字化软件从Kaplan-Meier生存曲线模拟个体患者水平数据。
主要发现
- 一年一期未辅助通畅率为64%,一期辅助通畅率为73%,二期通畅率为79%。
- 报告为成熟的瘘平均成熟时间为3.5个月,但仅26%的创建瘘在6个月时报告为成熟。
- 21%的瘘未使用即被废弃,总体感染风险为4.1%,每100个通路日感染率为0.018。
关键数值与推荐
- 一年一期未辅助通畅率64%,一期辅助通畅率73%,二期通畅率79%。
- 报告为成熟的瘘平均成熟时间3.5个月,6个月成熟率26%,废弃率21%。
- 总体感染风险4.1%,每100个通路日感染率0.018。
临床怎么用
- 临床评估动静脉瘘效用时应综合考虑成熟时间、成熟率、废弃率和感染风险,而非仅依赖通畅率。
- 需采用统一结局定义以准确比较不同研究中的瘘结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Arteriovenous fistulae are the currently recommended gold standard vascular access modality for haemodialysis because of their prolonged patency, improved durability, and low risk of infection for those that mature. However, notable disadvantages are observed in terms of protracted maturation time, associated high rates of catheter use, and substantial abandonment rates. The aim of this study was to quantitatively summarize the outcomes of fistula patency, infection, maturation, and abandonment published in the scientific literature. METHODS: This was a systematic review and meta-analyses of studies evaluating fistula outcomes. Literature searches were conducted in multiple databases to identify observational and interventional studies of mean fistula patency rates at 1 year, infection risk, maturation time, and abandonment. Digitisation software was used to simulate individual patient level data from Kaplan-Meier survival plots. RESULTS: Over 8000 studies were reviewed, and from these, 318 studies were included comprising 62,712 accesses. For fistulas the primary unassisted, primary assisted, and secondary patency rates at one year were 64%, 73% and 79% respectively, however not all fistulas reported as patent could be confirmed as being clinically useful for dialysis (i.e. functional patency). For fistulas that were reported as mature, mean time to maturation was 3.5 months, however only 26% of created fistulas were reported as mature at 6 months and 21% of fistulas were abandoned without use. Overall risk of infection in fistula patients was 4.1% and the overall rate per 100 access days was 0.018. CONCLUSIONS: Reported fistula patency rates may overstate their potential clinical utility when time to maturation, maturation rate, abandonment and infection are considered. Protracted maturation times, abandonment and infection all have a significant impact on evaluating the clinical utility of fistula creation. A rigorous and consistent set of outcomes definitions for hemodialysis access are necessary to clarify factors contributing to fistula success and the clinical consequence of fistula failure.
引用
- Bylsma LC, Gage SM, Reichert H, et al. Arteriovenous Fistulae for Haemodialysis: A Systematic Review and Meta-analysis of Efficacy and Safety Outcomes. Eur J Vasc Endovasc Surg. 2017. PMID: 28843984. doi:10.1016/j.ejvs.2017.06.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。